Take 2 capsules daily.

Helping support digestive and gastrointestinal health
through impacting gene expression, Tributyrin is the only
form to be clinically substantiated bioavailability in the
colon. It supports immune health by supporting tight
junctures in the intestinal lining normalizing inflammatory
responses in the gastrointestinal tract.

Butyrate prodrug Tributyrin is proven to
overcome the pharmacokinetic drawbacks of
butyrate supplementation while eliminating
bad smell and taste.

Cellular Pathways

The overexpression of GPx causes the blocking of the
NF-kB cascade, resulting in the attenuation of the
inflammatory response by impairing the expression of
NF-kB inflammatory genes.
Butyrate induces maturation and expansion of colonic
regulatory T cells
PPARy, strongly expressed in the colon, controls the energy
production required for microbiome homeostasis through
fatty acid oxidation.

Why this matters:

3 days of Abx administered by oral gavage resulted in an
early complete loss of bacterial groups. Despite outgrowth of
several resistant organisms, cecal contents from abx-treated
mice lost the ability to produce SCFAs from inulin and lost HIF
expression, both of which are restored by butyrate administration.
Butyrate is a potent activator of AMPK in colonic cell lines.
*Kelly, C. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial
HIF Augments Tissue BarrierFunction. Cell Host Microbe. 2015; 17(5): 662–671

Clinical Studies
nuButyrate™ Results

Butyrate prodrug Tributyrin is proven to overcome the pharmacokentic drawbacks of butyrate supplementation while eliminating bad smell and taste.  It has been clinically substantiated bioavailability in the colon. 
* who performed the study?

•    Faecalibacterium prausnitzii increased 41% over placebo
•    Anaerostipes increased 67% over placebo
•    Both bacteria are butyrate producers and their benefits are associated with butyrate production (healthy microbiome, immunity, healthy inflammatory response, etc.)

Tributyrin (as CoreBiome®) 

•     Is the #1 selling SCFA on the market
•    Has clinically substantiated bioavailability in the colon
•    In a 48-hour study using a gastrointestinal model [and that was repeated in a four-week study], CoreBiome® limited IL6, TNF-alpha and measurements of epithelial function through TEER (transepithelial electrical resistance), suggesting that it may support gut barrier function
•     Is the ONLY SCFA with marketable claims

Synergy with Larazotide, Guttides (BPC-157 + KPV):

Critical component of GI protocols including Guttides (BPC-157 + KPV), Larazotide and low dose pentosan polysulfate.

Larazotide + nuButyrate™ 
Larazotide protects the gut by improving and repairing tight junctions providing gut permeability protection. Larazotide improves the structure and integrity of the gut while nubutyrate works on creating the optimal environment through immune and inflammation modulation. 

Guttides + nuButyrate™
The combination of gut health peptides  BPC-157 and KPV improve inflammation and mucosal barrier integrity. nuButyrate is commonly used in conjunction to further improve the GI inflammatory state.